Dr. Coleman has more than 29 years of product development experience in the biotechnology, medical device, and pharmaceutical industries. During his career Dr. Coleman has:

• Successfully lead product focused research teams, headed the R&D function at a biotechnology subsidiary of a major pharmaceutical company, and served as CEO of a medical device company from start-up through regulatory approval and commercialization
• Managed successful IND filing and early clinical development of gene-based immunotherapies, overseen a large international phase 2 program of an angiogenesis therapy for critical limb ischemia that progressed to phase 3 trials at a large pharma commercial partner, and obtained approval under CE Mark and US FDA 510K for medical devices involved in tissue handling and cell preparation
• Raised over $15 million in equity funding and has extensive expertise in aligning development budgets with funding to meet regulatory requirements to efficiently and expeditiously move product development forward